Natural Health Malaysia
Natural Health Malaysia
Cervical Cancer Vaccine KILLS 61 American females, 18,000 more Injured
(Excerpt from CDC website: http://www.cdc.gov/vaccinesafety/vaccines/hpv/gardasil.html )
Reports of Health Concerns Following HPV Vaccination
HPV Vaccine Safety
There are two HPV vaccines, Gardasil and Cervarix, available to protect against the types of HPV that cause most cervical cancers.
The safety of the HPV vaccine was studied in clinical trials before it was licensed. For Gardasil, over 29,000 males and females participated in these trials. Cervarix was studied in over 30,000 females participating in several clinical trials performed all over the world. Cervarix has also been in use in other countries such as England and Europe prior to licensing from the Food and Drug Administration (FDA).
CDC and FDA have been closely monitoring the safety of HPV vaccines. There are 3 systems used to monitor the safety of vaccines after they are licensed and being used in the U.S. These systems can monitor adverse events already known to be caused by vaccines, as well as detect rare adverse events that were not identified during a vaccine's clinical trials. The 3 systems are:
•The Vaccine Adverse Event Reporting System (VAERS)–a useful early warning public health system that helps CDC and FDA detect possible side effects or adverse events following vaccination.
•The Vaccine Safety Datalink (VSD) Project–a project between CDC and 10 health organizations evaluate and monitor adverse events following vaccination.
•The Clinical Immunization Safety Assessment (CISA) Network–a project between 6 academic centers in the U.S. which conduct research on adverse events that might be caused by vaccines.
Reports to VAERS Following HPV Vaccination
As of February 14, 2011, approximately 33 million doses of Gardasil were distributed in the U.S. Since February 14, 2011, VAERS received a total of 18,354 reports of adverse events following Gardasil vaccination in the U.S. Of these reports, 92% were reports of events considered to be non-serious, and 8% were reports of events considered serious.*
Based on all of the information we have today, CDC recommends HPV vaccination for the prevention of most types of cervical cancer. As with all approved vaccines, CDC and FDA will continue to closely monitor the safety of HPV vaccines. Any problems detected with these vaccines will be reported to health officials, healthcare providers, and the public and needed action will be taken to ensure the public's health and safety.
VAERS Reports for Females Following Gardasil
VAERS defines non-serious adverse events as those other than hospitalization, death, permanent disability, and life threatening illness.
The vast majority (92%) of the adverse events reports following Gardasil vaccination have included fainting, pain, and swelling at the injection site (the arm), headache, nausea, and fever. Fainting is common after injections and vaccinations, especially in adolescents. Falls after fainting may sometimes cause serious injuries, such as head injuries, which can be prevented by closely observing the vaccinated person for 15 minutes after vaccination.
Non-serious adverse event reports
VAERS defines non-serious adverse events as those other than hospitalization, death, permanent disability, or life-threatening illness.
The vast majority (92%) of the adverse events reports following Gardasil vaccination have included fainting, pain, and swelling at the injection site (the arm), headache, nausea, and fever. Syncope (fainting) is common after injections and vaccinations, especially in adolescents. Falls after fainting may sometimes cause serious injuries, such as head injuries, which can be prevented by closely observing the vaccinated person for 15 minutes after vaccination.
Serious adverse event reports
Any VAERS report that indicated hospitalization, permanent disability, life-threatening illness, congenital anomaly or death is classified as serious. As with all VAERS reports, serious events may or may not have been caused by the vaccine.
Guillain-Barré Syndrome (GBS)
Guillain-Barré syndrome (GBS) has been reported after vaccination with Gardasil. GBS is a rare neurologic disorder that causes muscle weakness. It occurs in 1-2 out of every 100,000 people in their teens. A number of infections have been associated with GBS. There has been no indication that Gardasil increases the rate of GBS in girls and women above the rate expected in the general population, whether or not they were vaccinated.
Blood Clots
There have been some reports of blood clots in females after receiving Gardasil. These clots have occurred in the heart, lungs, and legs. Most of these people had a risk of getting blood clots, such as taking oral contraceptives (the birth control pill), smoking, obesity, and other risk factors.
Deaths
As of February 14, 2011, there have been 61 VAERS reports of death among females who have received Gardasil. Thirty two of these reports have been confirmed and 29 remain unconfirmed due to no identifiable patient information in the report such as a name and contact information to confirm the report. A death report is confirmed (verified) after a medical doctor reviews the report and any associated records. In the 32 reports confirmed, there was no unusual pattern or clustering to the deaths that would suggest that they were caused by the vaccine and some reports indicated a cause of death unrelated to vaccination.
VAERS Reports for Males Following Gardasil
Since recent approval of Gardasil for males, there have been 205 VAERS reports of which 15 were reports of serious adverse events. Of these 15 reports, 2 were reports of death―one confirmed and one unconfirmed. A death report is confirmed (verified) after a medical doctor reviews the report and any associated records. In the one confirmed there was no unusual pattern or clustering to the death that would suggest it was caused by the vaccine.
The other reported adverse events for males have a similar profile as described for all serious and non-serious reports above.
VAERS Reports Following Cervarix
Since licensed in October 2009, uptake of Cervarix in the U.S. has been low. As of October 2009, there have been 26 VAERS reports of adverse events following Cervarix vaccination in the U.S. The majority of these reports (96%) were considered to be non-serious
Thursday, February 24, 2011